Gritstone Oncology | search
Click here to view Gritstone Oncology news from 60+ newspapers.
Bookmark or Share- Gritstone bioGritstone’s goal is to develop groundbreaking immunotherapies for cancers and infectious diseases. Our approach focuses on generating a therapeutic immune response in these patients by unleashing the natural power of a patient’s immune system to recognize and destroy tumors or virally infected cells. It is well-established that one ...
- Our Pipeline - Gritstone bioOur first oncology program, GRANITE, is a personalized neoantigen-based vaccine. GRANITE is being evaluated in a Phase 2/3 study evaluating GRANITE as a maintenance treatment in patients with newly diagnosed, metastatic microsatellite-stable colorectal cancer (MSS-CRC) patients who have completed FOLFOX- bevacizumab induction therapy.
- Gritstone Announces Positive Clinical Data with GRANITE ...Gritstone develops its products by leveraging two key pillars—first, a proprietary AI -based platform, Gritstone EDGE TM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop, manufacture, and ...
- About - Gritstone bioGritstone bio is developing next-generation vaccines for cancer and infectious disease. Gritstone’s approach seeks to generate potent and durable immune responses by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens.
- Gritstone Announces First Patient Enrolled for Phase 2/3 ...Gritstone’s neoantigen-based immunotherapies are engineered to elicit a significant T-cell response (particularly CD8+ cytotoxic T cells) against mutation-derived tumor-specific neoantigens that are identified by the company using its proprietary Gritstone EDGE™ artificial intelligence platform.
More
